124results about "Antibacterial agents" patented technology

The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.

The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.

There are described novel 5-O-mycaminosyltylonide (OMT) analogs possessing increased antibacterial activity toward Gram positive and Gram negative bacteria as well as macrolide resistant Gram positives and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described are a method for treating bacterial infections by administering to a patient a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds

The invention relates to a tilmicosin soluble powder. The tilmicosin soluble powder is characterized by comprising the following ingredients in percentage by mass: 5-25% of tilmicosin, 3-15% of a cosolvent, 1-3% of a solubilizer, 3-8% of PEG and filler. The invention further provides a preparation method of the tilmicosin soluble powder. According to the tilmicosin soluble powder and the preparation method thereof disclosed by the invention, the preparation process is simple, only simple mixing is needed, the raw materials are all commercially available, low in price and easily available, and the obtained compound preparation is stable in performance; because of addition of the cosolvent and the solubilizer, the tilmicosin soluble powder is good in dissolving property, quite suitable for applications in clinic aspects, capable of meeting the relevant provisions of pharmacopoeia, suitable for industrialized large-scale production, and quite wide in application prospect. The tilmicosin soluble powder has a high practical value.

In part, the present invention is directed to compositions having a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions having a compound of formulas I-III and at least one other antibacterial agent.

The invention relates to a preparation of and compound injection formed by ª‰-lactam antibiotics and it and its application, which belongs to chemical chemical tragacanth . Make intosodium salt and kali salt, combined with ª‰-lactam antibiotics thy are then changes into powder injection; which can intravenous injection or intravenous drip with ª‰-lactam antibiotics at the sametime. It can remarktably increase the square below the curve, prolong half life of blood elimination (t1/2ª‰) of antibiotics, and the period of medicine density of ª‰-lactam antibiotics in blood surpassing that of the corresponding germ MIC; it can also reduce abuse of antibiotics, avoid generation and development of bacterial strain tolerant to medicine, has good safety and curative effect, stable quality and convenient use.

Methods for producing moxifloxacin hydrochloride compounds having very low levels of impurities are provided. Compounds produced using such methods and pharmaceutical compositions including such compounds are also provided.

The invention discloses compound ozone oil and a preparation method. The compound ozone oil is prepared from raw materials, namely 80-90 parts of camellia-seed oil, 10-30 parts of cnidium monnieri volatile oil and 5-15 parts of rhizoma atractylodis volatile oil, wherein the camellia-seed oil is subjected to ozone immobilization reaction, and the ozone oil of which the ozone content is 35-65g/L can be prepared. As the camellia-seed oil is adopted as base oil to prepare the ozone oil, and with the combination of the cnidium monnieri volatile oil and the rhizoma atractylodis volatile oil, the compound ozone oil is relatively wide in treatment field and relatively ideal in treatment effect. In addition, the compound ozone oil disclosed by the invention is scientific and reasonable in preparation process, and ozone can be stably immobilized without being volatilized and can be very well compounded with other traditional Chinese medicinal volatile oil, therefore, a synergic treatment function can be achieved.

The present invention provides an antibacterial wet wipe for skin care, which is prepared by adding an antibacterial skin care additive solution to a spunlaced non-woven fabric which is used as a base material, wherein the antibacterial skin care additive solution is prepared from the following components by mass fraction: Tea tree essential oil 5-10%, Nano silver 2-4%, Neroli essential oil 3-5%, Ceramide 1-1.5%, Glycerin 1-3%, Water-soluble vitamin E 0-3%, Emulsifier 0.1-0.5%, Deionized water balance. The preparation method of the antibacterial wet wipes for skin care is simple. And as adding the fungicides of tea tree essential oil and nano silver, and adding neroli essential oil, ceramide, glycerin, water-soluble vitamin E as moisturizing components, the antibacterial wet wipes for skin care of the invention not only have excellent antibacterial and disinfection effect, but also have whitening and moisturizing functions for skin care.

The invention provides a preparation method and application of cytochalasin compounds, and belongs to the technical field of medicinal chemistry. The cytochalasin compounds refer to cytochalasin C andcytochalasin D. The cytochalasin compounds are prepared by inoculating subprostrate sophora root endophytic fungus xylaria carbonisatus GDGJ-368 into a rice culture medium for fermentation, and carrying out silica gel column chromatography separation on a fermentation broth, the preservation number of the xylaria carbonisatus GDGJ-368 is CCTCC M2019951. The invention provides a new preparation method for the preparation of the cytochalasins C and D, and the method has positive significance for the development and utilization of the cytochalasin compounds. The obtained cytochalasins C and D have antibacterial activity on escherichia coli, bacillus subtilis, B hemolytic streptococcus and bacillus megatherium, and can be applied to preparation of antibacterial drugs.

The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin.

The invention relates to a method for keeping quality stability of clindamycin phosphate injection. The method is characterized by comprising the following steps of: (1) adding an antioxidant in an amount which accounts for 0.05 to 4 percent of the total mass of the clindamycin phosphate injection into the prepared clindamycin phosphate injection and fully stirring to dissolve the antioxidant; and (2) introducing nitrogen gas into the solution at the flow velocity of 2ml/minute for 10 to 20 minutes and sealing the injection, wherein the antioxidant is sodium sulfite. Because a certain amount of antioxidant is added into the clindamycin phosphate injection, clindamycin phosphate can be protected from being oxidized; and because the nitrogen gas is introduced into the clindamycin phosphate injection to replace oxygen in the solution, the clindamycin phosphate is protected from being oxidized; therefore, the clindamycin phosphate has stable quality in the solution and is difficult to degrade and oxidize; and the medication safety of the clindamycin phosphate is improved. The method is easy to operate, has low cost and contributes to wide popularization.

The present invention relates to sterilizing gel, and sterilizing gel containing chlorhexidine or its physiologically acceptable salt as active component. The sterilizing gel contains also stuffing, excipient, synergist and pH regulator.

The invention discloses a preparation method of aqueous-film-coated enterosoluble zinc oxide micro-pills. The aqueous-film-coated enterosoluble zinc oxide micro-pills are composed of the following ingredients: in per 100% by mass, 40-85% of zinc oxide, and 15-60% of auxiliary materials; (b), enterosoluble film coating layers of which the weight accounts for 5-30%, preferably 10-20%, of the weight of the zinc oxide micro-pill cores; and (c), particle size of the final zinc oxide micro-pills is 10-100 meshes, preferably 40-60 meshes. The aqueous-film-coated enterosoluble zinc oxide micro-pills are non-soluble in the stomach but soluble in the intestinal tract; and solution rate of the zinc oxide micro-pills in the intestinal tract is adjustable from 30 minutes to 3 hours, and thus, the zinc oxide can be uniformly dispersed in the intestinal tract. The aqueous-film-coated enterosoluble zinc oxide micro-pills have characteristics of common enterosoluble zinc oxide, namely the effects of preventing diarrhea and low dosage; moreover, usage of organic solvents in preparation processes of the enterosoluble zinc oxide is also avoided so that the preparation method of the aqueous-film-coated enterosoluble zinc oxide micro-pills is environmentally friendly, free of potential safety hazard, and capable of greatly improving economic benefits.

The invention relates to an azithromycin dispersible tablet and a preparation method thereof. The azithromycin dispersible tablet is prepared by the following steps: by adopting a fluid bed bottom spraying technology, coating azithromycin by using a suspension of calcium carbonate and a water-insoluble macromolecular polymer to prepare an azithromycin microcapsule; and then uniformly mixing the azithromycin microcapsule with other pharmaceutically acceptable auxiliary materials of the azithromycin and tabletting, wherein the water-insoluble macromolecular polymer is selected from one or more of acrylic resin, ethyecellulose and hydroxypropyl methylcellulose phthalate. Compared with the prior art, the azithromycin dispersible tablet disclosed by the invention has the advantages of good taste, fast dissolution and simple preparation process.

The invention belongs to the field of medicine and personal care, and particularly relates to propolis-aloe bacteriostatic gel and a preparation method thereof. The propolis-aloe bacteriostatic gel isprepared from the following raw materials in percentage by mass: 8-12% of golden cypress, 8-10% of fructus cnidii, 6-11% of stemona, 9-12% of fructus kochiae, 7-9% of divaricate saposhnikovia roots,4-8% of seaweeds, 3-6% of aloes, 0.5-0.8% of propolis, 1-1.4% of chlorhexidine acetate, 0.8-1.2% of carbomer 940, 0.08-0.11% of methylparaben, 0.09-0.12% of triethanolamine, 0.9-2.1% of ethanol and 36-40% of purified water. The propolis-aloe bacteriostatic gel is propolis-aloe gel prepared through the compound compatibility of the propolis and the aloes, through the synergistic effect of the propolis and the aloes, the effects of inhibiting the growth of bacteria, promoting wound healing, diminishing inflammation, realizing sterilization, realizing moistening and nourishing, replenishing water, removing acne, removing eczema and realizing spot-fading can be effectively achieved, and especially, the bacteriostatic effect on escherichia coli, staphylococcus aureus, hemolytic streptococcus and the like is achieved.

The invention relates to a composition for an oral cavity and application and a preparation method of the composition. The composition comprises the following components in parts by weight: 0.1-1 partof a lemon extract, 0.1-2 parts of a propolis extract, 0.05-0.8 part of a tea leaf extract, 0.5-5 parts of sea salt, 0.1-5 parts of an Aloe vera extract, 0.05-0.8 part of melaleuca alternifolia essential oil, 0.06-1 part of a white birch bark extract and 0.02-1 part of a mangnolia officinalis bark extract. By selecting components, on the basis of medicinal principles of different components, withthe combination of the components of a specific ratio, and by virtue of sufficient synergetic effects of the components, the composition provided by the invention has efficient effects of inhibitingbacteria, eliminating helicobacter pylori, relieving gum inflammation and treating ozostomia; meanwhile, the composition provided by the invention is reasonable in cost, simple and convenient to prepare, safe to use, relatively good in universality and relatively applicable to commercial popularization.

The invention discloses a preparation method of high-purity gynostemma pentaphylla total saponin for veterinary drugs. The preparation method is characterized in that a medicinal gynostemma pentaphylla total saponin medicinal material is used as a raw material, and the high-purity target product, namely the gynostemma pentaphylla total saponin for the veterinary drug, is obtained by high-efficiency extraction and separation on the basis of combination of technologies such as continuous countercurrent supersonic wave extraction, ceramic membrane microfiltration and macroporous resin adsorption separation with a conventional solvent reflux extraction principle. The preparation method has the advantages that the product purity and the product yield are improved, the product quality and the high quality are stabilized, the production cost is reduced, the requirements on the development of the high-purity gynostemma pentaphylla total saponin for the veterinary drugs and highly-processed products of gynostemma pentaphylla total saponin are satisfied, the production process is in line with environmental protection requirements, and the difficulty in the coordination of working procedures such as extraction, solvent recovery, enrichment and purification occurring in the volume production process of the gynostemma pentaphylla total saponin for the veterinary drugs is solved through the continuous improvement of the technology and the adjustment of technological processes and technical parameters.

The invention discloses an ephedra, almond gypsum and licorice granule pill. The ephedra, almond gypsum and licorice granule pill comprises a base pill (1) as the core, a medicine layer (2) obtained by mixing ephedra, almond gypsum and licorice granules, monoglyceride, hydroxy propyl methyl cellulose and acrylic resin, a coating layer (3) and a color coating layer (4), wherein the base pill (1) is coated with the medicine layer (2); the polymer slow-release coating layer (3) and the color coating layer (4) are sequentially coated layer by layer outwards. The invention solves the problems that ephedra, almond gypsum and licorice granules are short in half-life period and more frequent in administration, and makes up the shortfall in the prior art.

The invention provides a reinforced mosaic gene recombinant bacillus calmette-guerin, which comprises a recombinant shuttle expression vector guided into bacillus calmette-guerin (BCG) by an electro-transformation method and cloned with a bacillus tubercle mosaic gene Ag85A-ESAT6. The invention also provides a preparation method for the reinforced mosaic gene recombinant bacillus calmette-guerin and application thereof to preparation of recombinant vaccines for preventing tuberculosis. A mycobacterium differential expression system or other shuttle expression plasmid is used as the vector so as to realize high-level expression of the bacillus tubercle mosaic gene in the bacillus calmette-guerin. The reinforced mosaic gene recombinant bacillus calmette-guerin can produce reinforced TH1-type immune response aiming at Ag85A and ESAT-6 antigenic specificities respectively, and is expected to become a novel tuberculosis vaccine for replacing the bacillus calmette-guerin.